Is the Implantable Defibrillator Cost-effective?

  • S. Nisam
Conference paper


In the two decades since Mirowski and colleagues introduced the implantable cardioverter defíbrillator (ICD) into clinical practice [1], multiple clinical studies have established ICD therapy as the treatment of choice compared to any alternative treatment modality. Specifically, the ICD has been proven to be far superior in terms of overall survival and protection against sudden cardiac death from ventricular tachyarrhythmias in patients resuscitated from ventricular fibrillation or ventricular tachycardia (VF/VT) [2–12] as well as in patients identified as being at high risk despite not yet having suffered spontaneous episodes of VT or VF [13, 14]. However, the relatively high up-front costs — hospitalization and device - have focused much attention on the issue of the cost-effectiveness of ICD therapy [15]. Comparison of the cost-effectiveness of ICD therapy to that of presently well accepted medical therapies, particularly alternatives to ICD therapy, provides results which are enlightening and even surprising. Our article here will cover two main aspects of this question: (1) the conclusions and implications of the published studies on the cost-effectiveness of ICD therapy (ICD C-E); (2) the costs associated with ICD therapy compared to medical management and to other therapies.


Implantable Cardioverter Defibrillator Antiarrhythmic Drug Ventricular Tachyarrhythmia Implantable Cardioverter Defibrillator Therapy Implantable Defibrillator 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mirowski M, Reid P, Mower M et al (1980) Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 303:322–324PubMedCrossRefGoogle Scholar
  2. 2.
    Winkle R, Mead H, Ruder M et al (1989) Long-term outcome with the automatic implantable cardiover defibrillator. J Am Coll Cardiol 13:1353–1361PubMedCrossRefGoogle Scholar
  3. 3.
    Newman D, Sauve MJ, Herre J, Langberg JJ, Lee MA, Titus C, Franklin J, Scheinman MM, Griffin JC (1992) Survival after implantation of the cardioverter defibrillator. Am J Cardiol 69:899–903PubMedCrossRefGoogle Scholar
  4. 4.
    Böcker D, Block M, Isbruch F, Wietholt D, Hammel D, Borggrefe M, Breithardt G (1993) Do patients with an implantable defibrillator live longer? J Am Coll Cardiol 21:1638–1644PubMedCrossRefGoogle Scholar
  5. 5.
    Powell AC, Fuchs T, Finkelstein DM, Garan H, Cannom DS, McGovern BA, Kelly E, Vlahakes GJ, Torchiana DF, Ruskin JN (1993) Influence of implantable cardioverter defibrillators on the long-term prognosis of survivors of out-of-hospital cardiac arrest. Circulation 88:1083–1092PubMedCrossRefGoogle Scholar
  6. 6.
    Raviele A (1996) Implantable cardioverter defibrillator indications in 1996: have they changed? Am J Cardiol 78(5A):21–25PubMedCrossRefGoogle Scholar
  7. 7.
    Saksena S, Madan N, Lewis C (1996) Implantable cardioverter-defìbrillators are preferable to drugs as primary therapy in sustained ventricular tachyarrhythmias. Prog Cardiovasc Dis 38:445–454PubMedCrossRefGoogle Scholar
  8. 8.
    Böcker D, Block M, Borggrefe M, Breithardt G (1997) Defibrillators are superior to antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias. Eur Heart J 18:26–30PubMedCrossRefGoogle Scholar
  9. 9.
    Böcker D, Haverkamp W, Block M, Hammel D, Borggrefe M, Breithardt G (1996) Comparison of D,L-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. Circulation 94:151–157PubMedCrossRefGoogle Scholar
  10. 10.
    The Antiarrhythmics versus Implantable Defìbrillators (AVID) Investigators (1997) A comparison of antiarrhythmic-drug therapy with implantable defìbrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337:1576–1583CrossRefGoogle Scholar
  11. 11.
    Connolly S, on behalf of the CIDS investigators (1998) The Canadian Implantable Defìbrillator Study (CIDS): final results. Oral presentation at the annual session of the American College of Cardiology meeting, Atlanta, 29 March 1998Google Scholar
  12. 12.
    Kuck K-H, on behalf of the CASH investigators (1998) The Cardiac Arrest Study Hamburg (CASH): final results. Oral presentation at the annual session of the American College of Cardiology meeting, Atlanta, 29 March 1998Google Scholar
  13. 13.
    Moss A, Hall WJ, Cannom D et al (1996) Improved survival with an implanted defìbrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 335:1933–1940PubMedCrossRefGoogle Scholar
  14. 14.
    Buxton A (1999) Results from the Multicenter UnSustained Tachycardia Trial (MUSTT). Oral presentation during ”Hotline session: new-breaking clinical trials,” at the 48th Annual Scientific Sessions of the American College of Cardiology meeting, New Orleans, La, 8 March 1999Google Scholar
  15. 15.
    Levy S (1996) Is the implantable cardioverter-defìbrillator cost-effective? Eur Heart J 17:1458–1459PubMedCrossRefGoogle Scholar
  16. 16.
    Mushlin A, Zwanziger J, Gajary E, Andrews, M, Marron R (1997) Approach to cost-effectiveness assessment in the MADIT Trial. Am J Cardiol 80:33F–41FPubMedCrossRefGoogle Scholar
  17. 17.
    Larsen G, Manolis A, Sonnenberg F et al (1992) Cost effectiveness of the implantable cardioverter-defìbrillator: effect of improved batter life and comparison with amiodarone therapy. J Am Coll Cardiol 19:1323–1334PubMedCrossRefGoogle Scholar
  18. 18.
    Deering T, Weintraub W (1998) Cost-effectiveness of treatment options for sustained ventricular tachycardia and fibrillation: comparison of the implantable cardioverterdefìbrillator without prior electrophysiology testing to other treatment options. PACE 21:767 (abstr)Google Scholar
  19. 19.
    Anderson M, Camm A (1993) Implications for present and future applications of the implantable cardioverter-defìbrillator resulting from the use of a simple model of cost efficacy. Br Heart J 69:83–92PubMedCrossRefGoogle Scholar
  20. 20.
    Kupperman M, Luce B, McGovern B et al (1990) An analysis of the cost effectiveness of the ICD. Circulation 81:91–100CrossRefGoogle Scholar
  21. 21.
    Kuppersmith J, Hogan A, Guerrero P et al (1995) Evaluating and improving the cost effectiveness of the implantable cardioverter-defìbrillator. Am Heart J 130:507–515CrossRefGoogle Scholar
  22. 22.
    O’Donoghue S, Platia E, Brooks-Robinson S, Mispireta L (1990) ICD: is early implantation cost effective? J Am Coll Cardiol 16:1258–1263PubMedCrossRefGoogle Scholar
  23. 23.
    O’Brien B, Buxton M, Rushby J (1992) Cost effectiveness of the implantable cardioverter defìbrillator: a preliminary analysis. Br Heart J 68:241–245PubMedCrossRefGoogle Scholar
  24. 24.
    Valenti R, Schlapfer J, Fromer M, Fischer A, Kappenberger L (1996) Impact of the implantable cardioverter defìbrillator on rehospitalizations. Eur Heart J 17:1565–1571PubMedCrossRefGoogle Scholar
  25. 25.
    Owens D, Sanders G, Harris R, McDonald K et al (1997) Cost-effectivness of implantable cardioverter defìbrillators relative to amiodarone for prevention of sudden Cardiac Death. Ann Intern Med 126:1–12PubMedGoogle Scholar
  26. 26.
    Wever E, Hauer R, Schrijvers G, van Capelle F et al (1996) Cost-effectiveness of implantable defìbrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in post-infarction sudden death survivors: a randomized study. Circulation 93:489–496PubMedCrossRefGoogle Scholar
  27. 27.
    Mushlin A, Hall W, Zwanziger J et al (1998) The cost-effectiveness of automatic implantble cardiac defìbrillators: results from MADIT. Circulation 97:2129–2135PubMedCrossRefGoogle Scholar
  28. 28.
    NIH News Release (1997) NHLBI stops arrhythmia study -ICD reduces deaths. National Institutes of Health, Bethesda, Md, 14 April 1997Google Scholar
  29. 29.
    Cannom D (1998) AVID and Beyond: Lessons learned. J Intervent Cardiol 11:217–226CrossRefGoogle Scholar
  30. 30.
    Steinhaus D (1996) Economics: selection of candidates to ICD implant. In: Santini M (ed) Proceedings, progress in clinical pacing 1996. Futura, Armonk, pp 233–240Google Scholar
  31. 31.
    Schwabe U, Paffrath D (eds) (1998) Arzneiverordnungs-Report 1998. Springer, Berlin Heidelberg New YorkGoogle Scholar
  32. 32.
    Higgins S (1999) Impact of the multicenter automatic defìbrillator trial on implantable cardioverter defìbrillator indications trends. Am J Cardiol 83(5B):79–82CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2000

Authors and Affiliations

  • S. Nisam
    • 1
  1. 1.Guidant European HeadquartersZaventemBelgium

Personalised recommendations